CVE:DMA - DiaMedica Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
C$4.63 -0.10 (-2.11 %)
(As of 02/22/2019 04:00 PM ET)
Previous CloseC$4.73
Today's RangeC$4.56 - C$4.90
52-Week RangeC$3.33 - C$18.00
Volume27,300 shs
Average Volume6,619 shs
Market CapitalizationC$36.38 million
P/E Ratio-5.91
Dividend YieldN/A
BetaN/A
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Receive DMA News and Ratings via Email

Sign-up to receive the latest news and ratings for DMA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-763-4965454

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$503,657.00
Cash FlowC$0.50 per share
Book ValueC$0.17 per share

Profitability

Miscellaneous

Employees9
Market CapC$36.38 million
Next Earnings Date4/29/2019 (Estimated)
OptionableNot Optionable

DiaMedica Therapeutics (CVE:DMA) Frequently Asked Questions

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "DMA."

When is DiaMedica Therapeutics' next earnings date?

DiaMedica Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 29th 2019. View Earnings Estimates for DiaMedica Therapeutics.

Has DiaMedica Therapeutics been receiving favorable news coverage?

News headlines about DMA stock have been trending positive on Friday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. DiaMedica Therapeutics earned a news impact score of 2.7 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of DiaMedica Therapeutics' key competitors?

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include Lithium Americas (LAC), Energy Fuels (UUUU), Orion Group (ORN), SunOpta (STKL), Fibrocell Science (FCSC), Evolving Systems (EVOL), Pembina Pipeline (PBA), CVS Health (CVS), Bellicum Pharmaceuticals (BLCM) and Redline Communications Group (RDL).

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the folowing people:
  • Mr. Rick Pauls M.B.A., MBA, Pres, CEO & Director (Age 48)
  • Dr. Todd A. Verdoorn, Chief Scientific Officer (Age 58)
  • Mr. Scott B. Kellen C.A., CFO & Company Sec. (Age 54)
  • Mr. Edward B. Rady, Chief Commercial Advisor (Age 70)
  • Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 49)

How do I buy shares of DiaMedica Therapeutics?

Shares of DMA and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is DiaMedica Therapeutics' stock price today?

One share of DMA stock can currently be purchased for approximately C$4.63.

How big of a company is DiaMedica Therapeutics?

DiaMedica Therapeutics has a market capitalization of C$36.38 million and generates C$503,657.00 in revenue each year. DiaMedica Therapeutics employs 9 workers across the globe.

What is DiaMedica Therapeutics' official website?

The official website for DiaMedica Therapeutics is http://www.diamedica.com/.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 Carlson Pkwy N # N165, MINNEAPOLIS, MN 55447-4466, United States. The company can be reached via phone at +1-763-4965454.


MarketBeat Community Rating for DiaMedica Therapeutics (CVE DMA)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  37 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  101
MarketBeat's community ratings are surveys of what our community members think about DiaMedica Therapeutics and other stocks. Vote "Outperform" if you believe DMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2019 by MarketBeat.com Staff

Featured Article: Debt-To-Equity Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel